Registry of Patients Having Received oNKord® - Trial NCT05290662
Access comprehensive clinical trial information for NCT05290662 through Pure Global AI's free database. This phase not specified trial is sponsored by Glycostem Therapeutics BV and is currently Recruiting. The study focuses on AML. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Glycostem Therapeutics BV
Timeline & Enrollment
N/A
Jun 14, 2022
Mar 01, 2028
Primary Outcome
Incidence of SAEs related to oNKord® over time,Incidence of SAEs related to Cyclophosphamide-Fludarabine over time,Long-term follow-up on survival,Long-term follow-up on disease status,Long-term follow-up on cancer-related treatments
Summary
ReKORD is an observational study (Registry) enrolling participants who have received at least
 one dose of oNKord® (allogeneic ex vivo-generated Natural Killer [NK] cells from CD34+
 umbilical cord blood progenitor cells) in a clinical trial. Participants from multiple
 previous clinical trials of oNKord® can be enrolled in this Registry.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05290662
Non-Device Trial